Information about medicinal products published on this website is provided for informational purposes only and does not constitute advertising, a public offer, an offer for sale, or instructions for use.
The use of medicinal products is permitted only upon a doctor’s prescription. Consultations are provided by clinic specialists in person or online in accordance with applicable law.
The use of medicinal products is permitted only upon a doctor’s prescription. Consultations are provided by clinic specialists in person or online in accordance with applicable law.
ZOMIG Nasal Spray
contains zolmitriptan 5 mg in a single-dose dispenser for use during a migraine attack
Dosage and Administration
1. Gently blow your nose before use.
2. Remove the protective cap.
3. Close one nostril, insert the nozzle into the other; slightly tilt your head back, gently inhale and press the dispenser — you will hear a click.
4. Breathe deeply through your mouth for 5–10 seconds, then gently remove the nozzle.
5. One dose = 5 mg (one spray in one nostril).
6. If the effect is weak or symptoms return after ≥2 hours, a repeat dose is possible.
7. Do not exceed 2 doses (10 mg) within 24 hours.
8. Do not use more than 4 days a month — risk of medication-induced headaches.
Contraindications
Do not use if:
• You have ischemic heart disease, angina, or cardiac arrhythmias (including WPW syndrome);
• You have had a stroke, TIA, or vascular diseases;
• You have uncontrolled hypertension;
• You have known hypersensitivity to zolmitriptan or any components of the spray;
• You have taken other triptans or ergotamine medications in the last 24 hours;
• You have used MAO inhibitors less than 2 weeks ago;
• You have moderate or severe liver failure: the spray is not recommended in this form.
Special Instructions
• May cause an increase in blood pressure — monitor your BP.
• Fast-acting form is suitable for nausea or vomiting when tablets may not be absorbed.
• Possible side effects: unusual taste, tingling, dizziness, drowsiness, feeling of heat/cold, dry mouth, sore throat/chest pain.
• If cardiovascular symptoms occur (pain, chest tightness, rapid heartbeat) — stop taking and consult a doctor.
Storage and Disposal
• Store at 20–25°C, with the protective cap on, away from heat and children.
• Do not reuse the spray once used — dispose of after first use.
• Approved for the treatment of acute migraine in adults and adolescents aged 12 and older.
1. Gently blow your nose before use.
2. Remove the protective cap.
3. Close one nostril, insert the nozzle into the other; slightly tilt your head back, gently inhale and press the dispenser — you will hear a click.
4. Breathe deeply through your mouth for 5–10 seconds, then gently remove the nozzle.
5. One dose = 5 mg (one spray in one nostril).
6. If the effect is weak or symptoms return after ≥2 hours, a repeat dose is possible.
7. Do not exceed 2 doses (10 mg) within 24 hours.
8. Do not use more than 4 days a month — risk of medication-induced headaches.
Contraindications
Do not use if:
• You have ischemic heart disease, angina, or cardiac arrhythmias (including WPW syndrome);
• You have had a stroke, TIA, or vascular diseases;
• You have uncontrolled hypertension;
• You have known hypersensitivity to zolmitriptan or any components of the spray;
• You have taken other triptans or ergotamine medications in the last 24 hours;
• You have used MAO inhibitors less than 2 weeks ago;
• You have moderate or severe liver failure: the spray is not recommended in this form.
Special Instructions
• May cause an increase in blood pressure — monitor your BP.
• Fast-acting form is suitable for nausea or vomiting when tablets may not be absorbed.
• Possible side effects: unusual taste, tingling, dizziness, drowsiness, feeling of heat/cold, dry mouth, sore throat/chest pain.
• If cardiovascular symptoms occur (pain, chest tightness, rapid heartbeat) — stop taking and consult a doctor.
Storage and Disposal
• Store at 20–25°C, with the protective cap on, away from heat and children.
• Do not reuse the spray once used — dispose of after first use.
• Approved for the treatment of acute migraine in adults and adolescents aged 12 and older.
